Shopping Cart
Remove All
Your shopping cart is currently empty
Sugemalimab
😃Good
Catalog No. T76714Cas No. 2256084-03-2
Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma.
Sugemalimab
Sugemalimab
😃Good
Purity: 95%
Catalog No. T76714Cas No. 2256084-03-2
Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $539 | - | In Stock | |
| 5 mg | $1,380 | - | In Stock | |
| 10 mg | $2,120 | - | In Stock | |
| 25 mg | $3,900 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma. |
| In vitro | Sugemalimab (CS1001) specifically binds PD-L1, competitively blocking human PD-L1 from interacting with PD-1 and CD80, thereby inducing CD4+ T lymphocyte proliferation and enhancing IFN-γ and IL-2 production. Sugemalimab lacks antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) [2]. |
| In vivo | In a human PD-1 knock-in mouse model, Sugemalimab (CS1001) significantly inhibited tumor growth in subcutaneously implanted MC38-hPD-L1 mouse colon carcinomas, increased the cytotoxic T cell/regulatory T cell ratio, and markedly upregulated M1 macrophages while downregulating myeloid-derived suppressor cells (MDSCs) [2]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | PD-L1 |
| Cas No. | 2256084-03-2 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG4 lambda |
| Storage | store at low temperature | -20°C for 20 months | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Sugemalimab | purchase Sugemalimab | Sugemalimab cost | order Sugemalimab | Sugemalimab in vivo | Sugemalimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.